Development of Diagnostics and Treatment of Urological Cancers

Kidney Cancer Clinical Trial

— DEDUCER  

Official title:

Development of Diagnostics and Treatment of Urological Cancers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02994758
• Other study ID #: None yet
• Status: Recruiting
• Phase: N/A
• Start date: November 27, 2017
• Est. completion date: December 2025

Study information

• Verified date: March 2022
• Source: Helsinki University Central Hospital
• Contact: Antti S Rannikko, MD, PhD
• Phone: +35894711
• Email: antti.rannikko[@]hus.fi
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate whether state-of-the-art technologies such and next generation sequencing and drug sensitivity and resistance testing of patient derived tumour tissue can facilitate research translation and improve outcome of urologic cancers.

Description:

Access to high-quality clinical patient material (e.g. tissue of primary tumor and metastasis, plasma and urine) linked to comprehensive registry and clinical data and molecular characterization of the patient material using state-of-the-art technologies (e.g. NGS, transcriptomics, imaging, DSRT) will facilitate a more rapid translation of basic research innovations into clinical care (diagnostics, imaging, therapeutics) and result in improved outcome of patients suffering from urologic cancers ("personalized medicine"). The principal aim of the project is to establish a framework and infrastructure for the systematic collection and interpretation of biological patient samples. Similarly, the investigators aim to establish the format how the related clinical and research data can be made readily accessible for both clinicians and researchers without compromising patient privacy. The key objectives of the project are to facilitate research translation and to improve outcome of urologic cancers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient is able to provide written informed consent and is at least 18 years of age

2. The patient must have a verified diagnosis of an urologic cancer by a board-certified clinician

Exclusion Criteria:

1. The patient is not willing to provide a written informed consent

2. The patient has a severe psychiatric illness, imprisonment or mental impairment inflicting on ability to give informed consent

Related Conditions & MeSH terms

• Carcinoma
• Kidney Cancer
• Kidney Neoplasms
• Penile Cancer
• Penile Neoplasms
• Prostate Carcinoma
• Prostatic Neoplasms
• Testicular Cancer
• Testicular Neoplasms
• Urologic Neoplasms
• Urothelial Carcinoma

Intervention

Other:
• Personalised treatment
Treatment based on NGS or DSRT

Locations

Country	Name	City	State
Finland	Helsinki University Hospital	Helsinki	Uusimaa

Sponsors (2)

Lead Sponsor	Collaborator
Helsinki University Central Hospital	Karolinska Institutet

Country where clinical trial is conducted

Finland, 

References & Publications (2)

Saeed K, Ojamies P, Pellinen T, Eldfors S, Turkki R, Lundin J, Järvinen P, Nisen H, Taari K, Af Hällström TM, Rannikko A, Mirtti T, Kallioniemi O, Östling P. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug test — View Citation

Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, Peehl DM, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Östling P, Af Hällström TM. Comprehensive Drug Testing of Patient-derived Condit — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Successful clinical translation	The magnitude of successful clinical translation is measured by the number of times project-derived personalized medicine has impacted patients care by application of novel and existing biomarkers and therapies (e.g. sequencing, DSRT) by 2020	Up to 24 months
Secondary	Successful pre-clinical translation	Successful pre-clinical translation, the magnitude of which is measured by the number of times project-derived potential druggable targets or able to re-purpose treatment options were identified within the project by 2020.	Up to 24 months
Secondary	Translation of preclinical data into clinically useful data.	Translation of preclinical data into clinically useful data. The success of which is measured by the number of times preclinical data (e.g. sequencing, DSRT) was transformed into clinically useful form within 4 weeks from the time the initial sampling of the specimen was done.	Up to 24 months
Secondary	Number of representative cell models developed from clinical samples.	Representativeness is based on the genetics of the cell model and the parental tumor	Up to 24 months